Last reviewed · How we verify

AbobotulinumtoxinA dose 1 — Competitive Intelligence Brief

AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA dose 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Dermatology.

phase 2 Botulinum toxin Acetylcholine receptor Dermatology Biologic Live · refreshed every 30 min

Target snapshot

AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA dose 1) — Galderma R&D. AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscles to reduce muscle spasms and improve muscle tone.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AbobotulinumtoxinA dose 1 TARGET AbobotulinumtoxinA dose 1 Galderma R&D phase 2 Botulinum toxin Acetylcholine receptor
Ecclock SOFPIRONIUM BROMIDE Kaken Pharmaceutical marketed Muscarinic acetylcholine receptor M3 2024-01-01
Yupelri REVEFENACIN Mylan Ireland Ltd marketed Anticholinergic [EPC] Muscarinic acetylcholine receptor M3 2018-01-01
Northera DROXIDOPA Lundbeck Na Ltd marketed Catecholamine Muscarinic acetylcholine receptor M1 2014-01-01
Incruse Ellipta UMECLIDINIUM Glaxo Grp England marketed Anticholinergic Muscarinic acetylcholine receptor M4 2013-01-01
Toviaz FESOTERODINE Pfizer marketed fesoterodine Muscarinic acetylcholine receptor M2 2008-01-01
Toviaz Fesoterodine Fumarate Pfizer marketed fesoterodine Muscarinic acetylcholine receptor M2 2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

  1. Galderma R&D · 2 drugs in this class
  2. Hexsel Dermatology Clinic · 2 drugs in this class
  3. Seoul National University Hospital · 2 drugs in this class
  4. University of Utah · 2 drugs in this class
  5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
  6. EuBiologics Co.,Ltd · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Beth Israel Deaconess Medical Center · 1 drug in this class
  10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AbobotulinumtoxinA dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/abobotulinumtoxina-dose-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: